SUMO Inhibitor Compounds Targeting E1 Enzyme for Cancer Therapy
Solution Overview
Problem
Aberrations in post-translational modification of cellular proteins by the small ubiquitin-like modifier (SUMO) family, particularly the enzyme E1, are associated with the pathogenesis of life-threatening diseases such as cancer, neurodegenerative disorders, and viral infections, with E1 enzymes being overexpressed in cancer tissues and playing a crucial role in cancer proliferation and metastasis.
Innovation Solution
Administration of a compound with a specific formula that inhibits the E1 enzyme, formulated with a pharmaceutically acceptable excipient, to treat cancer by targeting the E1 enzyme, thereby regulating cellular functions and potentially reducing cancer cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If E1 enzyme levels are increased in cancer tissues to promote cancer proliferation, then cancer cell growth is enhanced, but this creates a therapeutic target for inhibition
Solution Approach 1:
The patent converts the harmful overexpression of E1 enzyme in cancer tissues into a beneficial therapeutic opportunity by designing inhibitors that specifically target this overexpressed enzyme. The high levels of E1 in cancer tissues, which initially promote cancer proliferation, now serve as abundant targets for inhibitor binding, enabling selective anti-cancer therapy.
Solution Approach 2:
Instead of trying to reduce E1 enzyme levels directly, the patent inverts the approach by using the overexpressed E1 enzyme as a target for inhibition. The therapy works by blocking the enzyme's function rather than reducing its expression, turning the cancer-promoting mechanism into a vulnerability that can be exploited therapeutically.
2Productivity
If SUMO-modification enzymes are targeted to inhibit cancer proliferation, then cancer cell growth is reduced, but specificity and selectivity of inhibition must be maintained
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that match the unique structural characteristics of the E1 enzyme's active site. The compounds contain specific functional groups and spatial arrangements that enable selective binding to E1 while avoiding off-target effects on other SUMO-modification enzymes, achieving both potency and selectivity.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that mediate the inhibition between the therapeutic goal and the E1 enzyme. These compounds serve as selective mediators that translate the therapeutic intent into specific molecular interactions with the enzyme, enabling controlled and selective inhibition of cancer cell proliferation.
Data Source
AI summary
There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme.



